NCT05988918View on ClinicalTrials.gov

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2029

Conditions
Pancreatic AdenocarcinomaAdenosquamous CarcinomaPancreatic Neuroendocrine TumorPancreatic Neuroendocrine CarcinomaGastrointestinal Neuroendocrine TumorGastrointestinal Neuroendocrine CarcinomaNeuroendocrine Prostate Carcinoma
Interventions
DRUG

ESK981

160 mg, PO, Once daily 5 days on and 2 days off

Trial Locations (3)

48109

RECRUITING

Rogel Cancer Center, Ann Arbor

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute, Detroit

53792

RECRUITING

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER